Please login to the form below
Seattle Genetics
This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.
AZ nabs US approval for new leukaemia drug Lumoxiti
Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Latest news
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.
-
Seattle Genetics claims key US approval for Adcetris
Seattle Genetics claims key US approval for Adcetris. Becomes the first new treatment for advanced Hl in more than 40 years. ... Seattle Genetics has won FDA approval for Adcetris as a first-line treatment for advanced Hodgkin’s lymphoma, which it
-
Takeda bags EU approval for Adcetris in lymphoma
Originally developed by Seattle Genetics, Adcetris has been on the market for just over six years and has seen sales grow steadily to around $600m last year, driven by a stream ... There are more new indications on the way, and Takeda and Seattle
-
Seattle Genetics' Adcetris earns FDA priority review status
Seattle Genetics' Adcetris earns FDA priority review status. The win follows a breakthrough designation from the US regulator last year. ... Seattle Genetics’Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the
-
Astellas extends phase III programme for Rydapt rival gilteritinib
It also has a 10-year-plus collaboration with Seattle Genetics covering microtubule-disrupting antibody-drug conjugates.
More from news
Approximately 6 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals in June 2015
NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
-
Deal Watch table for September 2014
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints CCO, Stephen Davies joins Eisai and more
Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
-
Douglas Williams named president and CEO of Codiak
These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
-
VentiRx appoints James Kyle Bryan as chief medical officer
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
-
Senior Medical Writer
-
Salary is DOE
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
-
Account Manager
-
Negotiable
-
Systematic Review Lead- London
-
Negotiable
- Account Director or Senior Account Director
-
Salary TBC
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
Subscribe to our email news alerts
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- The gene therapy revolution
- Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
Quick links
Infographics
